Anti-transcription intermediary factor 1 γ (TIF1γ) autoantibodies are associated, in adults with dermatomyositis, with an excess risk of cancer.
A French study involving clinicians from the Institute of Myology had shown in 2019 that anti-TIF1γ of IgG2 subtype could be a biomarker of this tumor risk. A result confirmed by a retrospective international study conducted under the aegis of the European NeuroMuscular Center in 132 adults with dermatomyositis with anti-TIF1γ:
- 54.5% had an associated cancer;
- their anti-TIF1γ IgG2 levels were higher than those of participants who did not develop cancer, on average 1.1 versus 0.50 AU/ml ;
- anti-TIF1γ IgG levels were also higher with associated cancer than without, 127.5 vs 93 AU/ml.